Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacogenomic and Pharmacoepigenomic Studies of Antipsychotic Drugs in First-Episode Schizophrenia

NCT07102069 is registered in ClinicalTrials.gov with Tianjin Anding Hospital as lead sponsor.

NCT NCT07102069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07102069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacogenomic and Pharmacoepigenomic Studies of Antipsychotic Drugs in First-Episode Schizophrenia
Lead sponsor
Tianjin Anding Hospital
Phase
Observational
Overall status
Completed
Start date
November 1, 2017
Completion date
September 14, 2022
Enrollment
384 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia